Multiple benefits of targeting inflammation in the treatment of type 2 diabetes

Diabetologia

Volumn 59, Issue 4, 2016, Pages 679-682

  Donath, Marc Y ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Inflammation; Review; Treatment; Type 2 diabetes

Indexed keywords

ANTIINFLAMMATORY AGENT; INTERLEUKIN 1BETA; SALSALATE; TUMOR NECROSIS FACTOR;

CARDIOVASCULAR DISEASE; HUMAN; INFLAMMATION; MACROPHAGE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME; DIABETES MELLITUS, TYPE 2; IMMUNOLOGY;

ANTI-INFLAMMATORY AGENTS; DIABETES MELLITUS, TYPE 2; HUMANS; INFLAMMATION;

EID: 84959463123     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-016-3873-z     Document Type: Review

References (33)

1. Donath MY (2014) Targeting inflammation in the treatment of type 2 diabetes: time to start. Nat Rev Drug Discov 13:465–476
2. Hotamisligil GS, Shargill NS, Spiegelman BM (1993) Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 259:87–91
3. Ofei F, Hurel S, Newkirk J, Sopwith M, Taylor R (1996) Effects of an engineered human anti-TNF-alpha antibody (CDP571) on insulin sensitivity and glycemic control in patients with NIDDM. Diabetes 45:881–885
4. Paquot N, Castillo MJ, Lefebvre PJ, Scheen AJ (2000) No increased insulin sensitivity after a single intravenous administration of a recombinant human tumor necrosis factor receptor: Fc fusion protein in obese insulin-resistant patients. J Clin Endocrinol Metab 85:1316–1319
5. Dominguez H, Storgaard H, Rask-Madsen C et al (2005) Metabolic and vascular effects of tumor necrosis factor-alpha blockade with etanercept in obese patients with type 2 diabetes. J Vasc Res 42:517–525
6. Bernstein LE, Berry J, Kim S, Canavan B, Grinspoon SK (2006) Effects of etanercept in patients with the metabolic syndrome. Arch Intern Med 166:902–908
7. Stanley TL, Zanni MV, Johnsen S et al (2011) TNF-α antagonism with etanercept decreases glucose and increases the proportion of high molecular weight adiponectin in obese subjects with features of the metabolic syndrome. J Clin Endocrinol Metab 96:E146–E150
8. Maedler K, Sergeev P, Ris F et al (2002) Glucose-induced beta-cell production of interleukin-1beta contributes to glucotoxicity in human pancreatic islets. J Clin Invest 110:851–860
9. Larsen CM, Faulenbach M, Vaag A et al (2007) Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med 356:1517–1526
10. Larsen CM, Faulenbach M, Vaag A, Ehses JA, Donath MY, Mandrup-Poulsen T (2009) Sustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes. Diabetes Care 32:1663–1668
11. Boni-Schnetzler M, Thorne J, Parnaud G et al (2008) Increased interleukin (IL)-1β messenger ribonucleic acid expression in beta-cells of individuals with type 2 diabetes and regulation of IL-1β in human islets by glucose and autostimulation. J Clin Endocrinol Metab 93:4065–4074
12. Herder C, Dalmas E, Boni-Schnetzler M, Donath MY (2015) The IL-1 pathway in type 2 diabetes and cardiovascular complications. Trends Endocrinol Metab 26:551–563
13. van Asseldonk EJ, Stienstra R, Koenen TB, Joosten LA, Netea MG, Tack CJ (2011) Treatment with Anakinra improves disposition index but not insulin sensitivity in nondiabetic subjects with the metabolic syndrome: a randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab 96:2119–2126
14. van Asseldonk EJ, van Poppel PC, Ballak DB, Stienstra R, Netea MG, Tack CJ (2015) One week treatment with the IL-1 receptor antagonist anakinra leads to a sustained improvement in insulin sensitivity in insulin resistant patients with type 1 diabetes mellitus. Clin Immunol 160:155–162
15. Yuan M, Konstantopoulos N, Lee J et al (2001) Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkβ. Science 293:1673–1677
16. Fleischman A, Shoelson SE, Bernier R, Goldfine AB (2008) Salsalate improves glycemia and inflammatory parameters in obese young adults. Diabetes Care 31:289–294
17. Goldfine AB, Silver R, Aldhahi W et al (2008) Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clin Transl Sci 1:36–43
18. Koska J, Ortega E, Bunt JC et al (2009) The effect of salsalate on insulin action and glucose tolerance in obese non-diabetic patients: results of a randomised double-blind placebo-controlled study. Diabetologia 52:385–393
19. Goldfine AB, Conlin PR, Halperin F et al (2013) A randomised trial of salsalate for insulin resistance and cardiovascular risk factors in persons with abnormal glucose tolerance. Diabetologia 56:714–723
20. Goldfine AB, Fonseca V, Jablonski KA et al (2010) The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial. Ann Intern Med 152:346–357
21. Goldfine AB, Fonseca V, Jablonski KA et al (2013) Salicylate (salsalate) in patients with type 2 diabetes: a randomized trial. Ann Intern Med 159:1–12
22. Ehses JA, Perren A, Eppler E et al (2007) Increased number of islet-associated macrophages in type 2 diabetes. Diabetes 56:2356–2370
23. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW Jr (2003) Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 112:1796–1808
24. Xu H, Barnes GT, Yang Q et al (2003) Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 112:1821–1830
25. Di Prospero NA, Artis E, Andrade-Gordon P et al (2014) CCR2 antagonism in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study. Diabetes Obes Metab 16:1055–1064
26. Haller HG, Menne J, Eulberg D (2015) CCL2 inhibition with emapticap pegol (NOX-E36) in type 2 diabetic patients with albuminuria. Diabetes 64(Suppl 1):A148, 580-P (Abstract)
27. Libby P, Ridker PM, Hansson GK, Leducq Transatlantic Network on A (2009) Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol 54:2129–2138
28. Dinarello CA, Simon A, van der Meer JW (2012) Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat Rev Drug Discov 11:633–652
29. Martinon F, Petrilli V, Mayor A, Tardivel A, Tschopp J (2006) Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440:237–241
30. So A, de Smedt T, Revaz S, Tschopp J (2007) A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther 9:R28
31. Vitale A, Cantarini L, Rigante D, Bardelli M, Galeazzi M (2015) Anakinra treatment in patients with gout and type 2 diabetes. Clin Rheumatol 34:981–984
32. Yeung H, Takeshita J, Mehta NN et al (2013) Psoriasis severity and the prevalence of major medical comorbidity: a population-based study. JAMA Dermatol 149:1173–1179
33. Ridker PM, Thuren T, Zalewski A, Libby P (2011) Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). Am Heart J 162:597–605